Compare Dishman Pharma with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs DIVIS LABORATORIES - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA DIVIS LABORATORIES DISHMAN PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 25.1 58.8 42.7% View Chart
P/BV x 3.3 13.5 24.7% View Chart
Dividend Yield % 0.7 0.5 147.2%  

Financials

 DISHMAN PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
DIVIS LABORATORIES
Mar-19
DISHMAN PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs3741,639 22.8%   
Low Rs1291,115 11.6%   
Sales per share (Unadj.) Rs197.8186.3 106.2%  
Earnings per share (Unadj.) Rs21.251.0 41.6%  
Cash flow per share (Unadj.) Rs34.757.3 60.6%  
Dividends per share (Unadj.) Rs2.0016.00 12.5%  
Dividend yield (eoy) %0.81.2 68.4%  
Book value per share (Unadj.) Rs179.9261.8 68.7%  
Shares outstanding (eoy) m80.69265.47 30.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.37.4 17.2%   
Avg P/E ratio x11.927.0 43.9%  
P/CF ratio (eoy) x7.224.0 30.2%  
Price / Book Value ratio x1.45.3 26.6%  
Dividend payout %9.431.4 30.0%   
Avg Mkt Cap Rs m20,306365,592 5.6%   
No. of employees `0000.811.8 7.0%   
Total wages/salary Rs m5,3555,423 98.7%   
Avg. sales/employee Rs Th19,252.74,175.1 461.1%   
Avg. wages/employee Rs Th6,459.5457.7 1,411.2%   
Avg. net profit/employee Rs Th2,064.11,141.8 180.8%   
INCOME DATA
Net Sales Rs m15,96149,463 32.3%  
Other income Rs m2651,556 17.1%   
Total revenues Rs m16,22651,019 31.8%   
Gross profit Rs m4,10318,718 21.9%  
Depreciation Rs m1,0911,689 64.6%   
Interest Rs m94435 2,698.3%   
Profit before tax Rs m2,33418,551 12.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6245,023 12.4%   
Profit after tax Rs m1,71113,527 12.6%  
Gross profit margin %25.737.8 67.9%  
Effective tax rate %26.727.1 98.7%   
Net profit margin %10.727.3 39.2%  
BALANCE SHEET DATA
Current assets Rs m11,01846,501 23.7%   
Current liabilities Rs m9,5178,468 112.4%   
Net working cap to sales %9.476.9 12.2%  
Current ratio x1.25.5 21.1%  
Inventory Days Days110131 84.5%  
Debtors Days Days3586 40.6%  
Net fixed assets Rs m16,30425,797 63.2%   
Share capital Rs m161531 30.4%   
"Free" reserves Rs m12,90768,962 18.7%   
Net worth Rs m14,51669,493 20.9%   
Long term debt Rs m4,1890-   
Total assets Rs m29,80580,383 37.1%  
Interest coverage x3.5531.0 0.7%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.50.6 87.0%   
Return on assets %8.916.9 52.8%  
Return on equity %11.819.5 60.6%  
Return on capital %17.526.7 65.5%  
Exports to sales %24.80-   
Imports to sales %3.724.6 15.2%   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m59612,187 4.9%   
Fx inflow Rs m4,95241,238 12.0%   
Fx outflow Rs m69712,405 5.6%   
Net fx Rs m4,25528,833 14.8%   
CASH FLOW
From Operations Rs m2,7869,543 29.2%  
From Investments Rs m-1,529-6,854 22.3%  
From Financial Activity Rs m-941-2,459 38.3%  
Net Cashflow Rs m316230 137.8%  

Share Holding

Indian Promoters % 61.4 52.0 118.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 11.8 31.4%  
FIIs % 12.7 19.0 66.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 17.2 128.5%  
Shareholders   46,261 31,796 145.5%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   SUN PHARMA  ORCHID PHARMA  SANOFI INDIA  FULFORD INDIA  PROCTER & GAMBLE HEALTH  

Compare DISHMAN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Plunges 746 Points; Banking & Metal Stocks Bleed(Closing)

Indian share markets witnessed huge selling pressure today and extended losses as the session progressed, dragged down by heavy selling in metal and banking stocks.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY20); Net Profit Down 4.9% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 4.9% YoY). Sales on the other hand came in at Rs 14 bn (up 3.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (2QFY20); Net Profit Down 10.3% (Quarterly Result Update)

Nov 11, 2019 | Updated on Nov 11, 2019

For the quarter ended September 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 10.3% YoY). Sales on the other hand came in at Rs 14 bn (up 12.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES 2018-19 Annual Report Analysis (Annual Result Update)

Oct 10, 2019 | Updated on Oct 10, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

More Views on News

Most Popular

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS